|Articles|April 1, 2016
- Pharmaceutical Executive-04-01-2016
- Volume 36
- Issue 4
Pharmaceutical Executive, April 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
Closing the Gaps in Drug Chain of Custodyover 9 years ago
Data Unleashed: Cooperation Among Competitorsover 9 years ago
Raising the Stakes On Value-Based Pricingover 9 years ago
The Diversity Dearth in Pharmaover 9 years ago
Information in Action: A Conversation with Barbara Lopez Kunzover 9 years ago
R&D Model Mixes Compassion, Calculationover 9 years ago
Pressure Builds to Revamp Off-Label Marketing Rulesover 9 years ago
Drug Compounding: A Cause and Cure for High Drug Prices?over 9 years ago
The Odd Coupleover 9 years ago
Country Report: EgyptNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
2
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
The Situation We Faced: The Development and Commercialization of MariTide
5
